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Background: Over 20 distressing gastrointestinal symptoms affect many patients after pelvic 
radiotherapy, but in the United Kingdom few are referred for assessment. Algorithmic-based 
treatment delivered by either a consultant gastroenterologist or a clinical nurse specialist has 
been shown in a randomized trial to be statistically and clinically more effective than provision 
of a self-help booklet. In this study, we assessed cost-effectiveness.
Methods: Outcomes were measured at baseline (pre-randomization) and 6 months. Change in 
quality-adjusted life years (QALYs) was the primary outcome for the economic evaluation; a 
secondary analysis used change in the bowel subset score of the modified Inflammatory Bowel 
Disease Questionnaire (IBDQ-B). Intervention costs, British pounds 2013, covered visits with 
the gastroenterologist or nurse, investigations, medications and treatments. Incremental out-
comes and incremental costs were estimated simultaneously using multivariate linear regression. 
Uncertainty was handled non-parametrically using bootstrap with replacement.
Results: The mean (SD) cost of treatment was £895 (499) for the nurse and £1101 (567) for 
the consultant. The nurse was dominated by usual care, which was cheaper and achieved better 
outcomes. The mean cost per QALY gained from the consultant, compared to usual care, was 
£250,455; comparing the consultant to the nurse, it was £25,875. Algorithmic care produced better 
outcomes compared to the booklet only, as reflected in the IBDQ-B results, at a cost of ~£1,000.
Conclusion: Algorithmic treatment of radiation bowel injury by a consultant or a nurse results 
in significant symptom relief for patients but was not found to be cost-effective according to 
the National Institute for Health and Care Excellence (NICE) criteria.
Keywords: pelvic radiotherapy, algorithmic care, gastroenterologist, clinical nurse specialist
Introduction
Up to 23 distressing gastrointestinal symptoms, including fecal incontinence, defeca-
tory urgency, loose stools and abdominal pain, have been described to affect up to half 
of all patients who have undergone radiotherapy to treat a cancer in the pelvis.1,2 In the 
UK, however, only a small minority of survivors are ever referred for treatment for 
these symptoms, despite the serious repercussions they have on their quality of life.3,4 
Although previously considered refractory, a three-arm clinical randomized controlled 
trial (RCT) (ORBIT), completed in 2012, has shown that such chronic symptoms of 
radiation-induced bowel injury can be improved by algorithm-based treatment led 
by either a gastroenterologist or a clinical nurse specialist.5 The primary end point in 
this study was the bowel subset score of the Modified Inflammatory Bowel Disease 
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Questionnaire (IBDQ-B).6,7 A statistically and clinically 
significant improvement in IBDQ-B was recorded for both 
the gastroenterologist group and the nurse group, when com-
pared to a control group who were given a self-help booklet.5 
The step-by-step algorithm was designed prior to the trial 
through a series of pilot studies that tested investigations 
and sequential treatments for the 23 symptoms that develop 
after radiotherapy.8–13 Application of the algorithm means 
that patients receive tests and treatments that are tailored to 
their individual needs.
Because of rising healthcare costs and limited budgets, 
new treatments are increasingly required to demonstrate value-
for-money as well as clinical efficacy. This article reports the 
economic evaluation of the ORBIT trial. The costs of imple-
menting the algorithm by both the gastroenterologist and the 
nurse, and the findings from a cost-effectiveness analysis, are 
presented. Each professional is compared with the control 
(booklet) condition, and with each other. The primary analy-
sis was a cost-utility analysis where the effectiveness metric, 
quality-adjusted life years (QALYs), reflects morbidity or 
health-related quality of life associated with the alternative 
strategies. QALYs provide a common unit of measurement 
through which the value of interventions in different areas 
can be compared.14 The National Institute for Health and Care 
Excellence (NICE), which provides guidance and quality 
standards for health, public health and social care in the UK, 
uses a threshold cost per QALY gained of between £20,000 and 
£30,000 to determine the cost-effectiveness in health technol-
ogy appraisals.15 The secondary analysis concerned the cost per 
unit of therapeutic gain from the algorithm, using the IBDQ-B.
Methods
Participants
The ORBIT trial was conducted at the Royal Marsden 
Hospital in London between 2007 and 2011. Full details 
have been published elsewhere.5 Participants were aged 
18 years or older, with persisting bowel symptoms that 
had started either during or following pelvic radiotherapy 
given curatively for various urological, gynecological and 
gastrointestinal cancers. They had to be well enough to 
travel to and from the hospital and be treated as outpatients. 
To be eligible, radiotherapy must have completed at least 
6 months prior to enrollment in the study. Patients were 
excluded if they had serious comorbidities, metastatic 
disease, short life expectancy (<1 year), a colostomy or 
ileostomy (unless reversed more than 6 months previously) 
or been assessed previously by a gastroenterologist for 
the symptoms. Patients were withdrawn from the study if 
they required treatment for recurrence of cancer or were 
hospitalized for the treatment of gastrointestinal symptoms 
during the study.
Recruitment and data collection
Potentially eligible patients were identified through the 
hospital radiotherapy department. Clinical records were 
searched for current or past patients meeting the eligibility 
criteria. Invitations to participate were delivered either by 
direct contact at normal patient follow-up appointments, 
or by telephone and/or mail. Patients referred to a routine 
National Health Service (NHS) outpatient clinic specializing 
in post-radiotherapy bowel symptoms for non-urgent treat-
ment were also invited to take part.
All volunteers were screened for eligibility and invited to 
attend an outpatient clinic to complete consenting processes 
and provide baseline information. Participants were then 
randomized (block randomization stratified by tumor site 
and degree of bowel dysfunction, that is, IBDQ-B <60 or 
≥60) to one of three treatment groups: usual care (consisting 
of a self-help booklet), specialist nurse-led algorithmically 
driven care and consultant gastroenterologist-led algorithmi-
cally driven care. The trial duration was 1 year. Data were 
collected at baseline, 6-month and 12-month follow-up. At 
the 6-month follow-up, patients in the usual care (booklet) 
arm were given the option to transfer to the consultant arm 
if they had persisting gastrointestinal symptoms. For this 
reason, the analysis was conducted at the 6-month time point.
Health outcome measures
The primary outcome for the economic evaluation was 
a participant’s QALY, obtained from Medical Outcomes 
Study’s Short Form 12 health survey (SF-12) scores that were 
gathered at each assessment point. SF-12 is a well-validated 
and widely used generic measure of health-related quality 
of life that incorporates general health, mental health, pain, 
vitality, and physical, social and emotional functioning across 
12 items.16 Responses can be converted to a reduced six 
dimension score (the SF-6D), which can be used to estimate 
single health utility index scores ranging from 0 (death) to 1 
(perfect health) using standardized utility weights.17 These 
utility scores were then mapped to EQ-5D (EuroQoL) using 
a published procedure.18,19 EQ-5D is the widely used generic 
instrument, with a UK utility tariff,20 which is favored by 
NICE to estimate health utility index scores. Using EQ-5D 
mapped utility estimates allows direct comparability of the 
cost-effectiveness results to other studies conducted using 
the EQ-5D to elicit QALY values. To provide an estimate of 
a participant’s QALYs accrued over the 6-month time period, 
the area under the curve between baseline and 6 months was 
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calculated using the trapezoid method (also known as discrete 
time integration).
Secondary analysis was conducted using the IBDQ-B 
change from baseline (the primary outcome for the clinical 
study),5 in place of the patient’s QALY. Being a condition-
specific measure of health-related quality of life with scores 
ranging from 10 (worst possible bowel function) to 70 
(perfect), the IBDQ-B is more sensitive to small changes 
in patient outcomes that may not be detected by the generic 
EQ-5D scale. A shift of six or more points in the IBDQ-B is 
considered to be a clinically relevant change from the patient 
perspective.21
Costs
The cost of the intervention is made up of several elements: 
the number and duration of visits with either the consultant 
gastroenterologist or the clinical nurse specialist, and the cost 
of any investigations and treatments delivered as part of the 
algorithm, including medications. All costs were calculated at 
the individual patient level in British pounds, 2013, and mea-
sured from the perspective of the National Health Service.
The intervention consisted of an initial meeting with the 
consultant or the nurse, at which the patients’ symptoms were 
assessed and tests and treatments were ordered according to 
the algorithm. Additional follow-up visits with the consul-
tant or the nurse were arranged, as required. Unit costs for 
clinical contact were fully absorbed, inclusive of oncosts 
and overheads, and obtained from NHS reference costs,22 or 
Department of Health sources.23 The duration of the initial 
meeting was recorded in minutes, and the cost was calcu-
lated pro rata. For any subsequent outpatient appointments, 
the duration is not known so these follow-up sessions were 
assumed to have a 15-minute duration for both the consultant-
led and nurse-led intervention arms. The investigations and 
treatments delivered to patients were retrieved from patient 
notes at the end of the study, and costs were provided by the 
hospital finance department. All cost elements were summed 
to provide a total cost per patient of the intervention over the 
first 6 months.
Analysis
All economic analyses were conducted using STATA13 
(Stata Statistical Software, release 13; StataCorp LP, Col-
lege Station, TX, USA). Results presented are based on a 
complete case analysis for those subjects with complete data 
at baseline and 6 months, covering resource use, IBDQ-B 
and SF-12. Three sets of analysis were conducted: nurse-
led intervention was compared with usual care (booklet), 
consultant-led  intervention was compared with usual care 
and, finally, consultant-led care was compared directly with 
nurse-led care.
Cost utility (QALY)
The cost-effectiveness of the intervention was assessed as 
an incremental cost-effectiveness ratio (ICER). This is the 
incremental cost per QALY gained, when moving from 
usual care (booklet arm) to either nurse-led algorithmic 
care, consultant-led algorithmic care or comparing nurse 
with consultant.
The incremental costs and incremental QALYs were esti-
mated simultaneously using a seemingly unrelated regression 
(SUR). No covariates were included for estimation of costs. 
However, in the QALY equation, baseline utility score was 
included to control for patient-level differences at baseline.24
Uncertainty was handled non-parametrically using boot-
strap with replacement.25 Samples (n=10,000) of equal size 
to the original sample were drawn, and the incremental costs 
and QALYs were estimated using the SUR for each of the 
bootstrap samples. The results of this process are presented 
on a cost-effectiveness plane. In addition, the probability that 
each treatment would be deemed cost-effective at the NICE 
threshold willingness to pay of £20,000–£30,000 per QALY 
was calculated and presented in a cost-effectiveness acceptabil-
ity curve and cost-effectiveness acceptability frontier (CEAF).
Cost-effectiveness (IBDQ-B)
The same non-parametric bootstrap sampling approach was 
used, as described earlier, using the IBDQ-B outcomes, and 
the results were presented as cost per six-point (clinically 
relevant) change in IBDQ-B score.
Ethical considerations
The ORBIT study gained a favorable ethical opinion follow-
ing review by the Royal Marsden Research Ethics Committee 
(later named NRES Committee London – Chelsea), reference 
07/Q0801/47. All participants provided informed written 
consent for their data to be used in the study. The trial is 
registered with ClinicalTrials.gov, number NCT00737230.
Results
Characteristics of participants
Of 2,484 patients assessed for eligibility, 218 participated 
and the rest were ineligible (n=876), not contactable (185), 
reported no new symptoms (934) or refused (271).5 At ran-
domization, 68, 80 and 70 participants were allocated to the 
usual care (booklet), nurse-led algorithmic care and consul-
tant-led algorithmic care groups, respectively. At 6 months, 
loss to follow-up and withdrawals from the study reduced 
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these sample sizes to 57, 62 and 59, respectively (n=178). Of 
these 178 participants, 159 (47, 61, 51) had complete data on 
the SF-12 at baseline and 6 months, sufficient to estimate a 
health utility index. Three of the 159 patients had no infor-
mation captured on the duration of their baseline clinical 
consultation, so simple imputation was applied using the 
mean duration for the appropriate treatment arm, rather than 
dropping the patients from the analysis. There were 182 (57, 
66, 59) patients with IBDQ-B data at baseline and 6 months.
Costs
Based on those patients with complete data for costs and SF-12 
at baseline and 6 months, the unconditional mean (SD) cost 
of treatment was £895 (499) and £1101 (567) for nurse and 
consultant-led treatments, respectively (Table 1). The consul-
tant was more costly than the nurse in clinical time (due to 
higher unit costs) and in use of investigations and prescribing. 
The higher value of medications in the consultant arm is driven 
by a few outliers (median [interquartile range] medication 
cost £1.05 (0–35) for nurse and £25.80 (0–35) for consultant). 
When the complete case sample was delimited based on IBDQ-
B rather than SF-12, the sample size increased marginally, but 
this did not result in a significant change in resource use or 
costs (Table 1). The cost of treatment for the usual care arm 
(booklet) is treated as zero, since there is no required clinical 
contact, or additional prescription of medication.
Outcomes
All three treatment arms saw small improvements in utility 
between baseline and 6-month follow-up, the smallest mean 
increase being in the nurse-led arm. None of the changes 
were statistically significantly different from zero. The mean 
QALY gains over the 6-month period in the consultant and 
nurse arms were not significantly different from those in the 
booklet arm, and there was no significant difference between 
the improvements in the nurse or consultant groups (Table 2).
The mean IBDQ-B scores improved in all three groups 
over the 6 months. The change in the mean IBDQ-B score 
was larger in the consultant than nurse arm, but the difference 
between these two changes was not statistically significant. 
However, the changes in both intervention arms were signifi-
cantly larger than the change in the booklet arm.
Cost-utility analysis
In the cost-utility analysis (Table 3; Figure 1), the nurse-led 
arm was dominated by the usual care (booklet arm), being 
more expensive and having worse health (QALY) outcomes 
in approximately two thirds of the 10,000 sampling realiza-
tions. The consultant-led treatment, compared to usual care, 
was more expensive but led to better health outcomes in 
more than half of the sampling realizations (mean cost per 
QALY gained [ICER]=£250,455). When the consultant-led 
treatment is compared to the nurse-led treatment, there is a 
small incremental cost, but in the majority of sampling real-
izations, the consultant-led treatment resulted in better health 
outcomes (mean cost per QALY gained [ICER]=£25,875).
For each of the 10,000 realizations, the three treatments 
can be ranked in terms of which yielded the most cost-effective 
result for a given willingness to pay per QALY. The frequency 
of ‘wins’ from these rankings over the 10,000 samples is an 
estimate of the probability the treatment would be deemed the 
most cost-effective when compared to the alternatives. This 
analysis generates the CEAF. The nurse-led treatment option 
is dominated by both the booklet and consultant-led treatment 
options. At the lower willingness to pay per QALY, the booklet 
is favored and, at a WTP of £30,000 (the upper limit normally 
imposed by NICE), the booklet arm is predicted to have a 
near 100% likelihood of being the most cost-effective. Above 
Table 1 Resources and costs (British pounds 2013)
Treatment 
group
N Baseline consultation duration  Additional consultationsa Investigations, 
treatments
Medications Total cost 
Mean (min) SD (min) Costb (£) Mean, n SD Costb (£) Mean  
costc (£)
SD Mean 
costd (£)
SD Mean (£) SD
Based on participants with SF-12 (QALY) data at baseline and 6 months
Nurse 61 47.5 21.5 70 1.03 0.86 22.66 786 493 17 23.77 895 499
Consultant 51 29.7 15.8 162 0.98 0.95 80.12 793 527 66 152.46 1101 567
Based on participants with IBDQ-B data at baseline and 6 months
Nurse 66 47.8 20.9 70. 1.03 0.86 22.66 768 494 17 23.25 878 498
Consultant 59 29.4 14.9 159 1 1 82.60 764 536 69 166.7 1075 580
Notes: aDuration based on 15-minute consultation.  bUnit costs for specialist nurse is £88/hour23 and for gastroenterologist is £162/consultation of 30 minutes.22 cCosts of 
investigations and treatments supplied by the hospital finance department: abdominal X-ray £49.95; anal ultrasound £77.23; bloods battery £75.12; colonoscopy £683.00; CT 
scan £120.34; flexible sigmoidoscopy £436.95; breath test £142.28; MRI scan £288.97; SehCAT scan £265.00; stool culture £28.13; endoscopy £491.56; fecal elastase £15.76; 
liver ultrasound £77.23. dTotal cost of medications per patient supplied by clinical team.
Abbreviations: CT, computerised tomography; IBDQ-B, Inflammatory Bowel Disease Questionnaire; MRI, magnetic resonance imaging; QALY, quality-adjusted life year; 
SehCAT scan, selenium homocholic acid taurine scan; SD, standard deviation; SF-12, Medical Outcomes Study’s Short-Form 12.
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a WTP of ~£250,000 per QALY gained, the consultant-led 
treatment is favored with ~52% probability of being the most 
cost-effective treatment option (Figure 1). This result suggests 
that although the consultant-led treatment leads to marginally 
better treatment outcomes on average, than either usual care 
(booklet) or the nurse-led treatment, the gain in QALY is too 
small to offset the relatively high incremental cost.
Cost-effectiveness analysis
Results of the probabilistic analysis using the IBDQ-B 
change from baseline differ from those using the QALY as 
the outcome measure (Table 3; Figure 2). For the IBDQ-B 
analysis, the bootstrap samples, for both the comparison of 
the consultant and the nurse with the booklet arm, are to 
the right of the zero line indicating both achieved a benefit 
compared to the usual care/booklet arm.
The CEAF suggests that at lower willingness to pay per 
6-point gain in IBDQ-B score, the booklet has the highest 
probability of being the most cost-effective intervention. 
At ~£1280, this shifts in favor of the nurse-led arm, which 
has ~45% probability of being the most cost-effective inter-
vention. Beyond a willingness to pay of £2000 per 6-point 
IBDQ-B change, the consultant-led intervention is favored 
at a probability of ~50%. This probability tends asymptoti-
cally towards a probability of ~62% as the willingness to 
pay increases to £8000. This shift towards the consultant-led 
intervention is driven by the marginally better health out-
comes this intervention achieved. However, without a defined 
threshold willingness to pay per 6-point change in IBDQ-B 
score, which is independently justifiable (equivalent to the 
NICE £30,000 per QALY), it is hard to make a judgment over 
which intervention is most favored by this analysis. Both the 
nurse- and consultant-led intervention achieve better health 
outcomes, as measured using the IBDQ-B; however, on 
average neither have a high likelihood of being deemed the 
most cost-effective, when compared to the booklet arm alone.
Table 2 Outcomes
Treatment group N Utility score 
(baseline) 
Utility score 
(6 months) 
Incremental QALYs 
gained versus booklet 
groupa
Utility SD Utility SD Mean SD
Based on participants with SF-12 (QALY) data at baseline and 6 months
Booklet 47 0.776 0.200 0.797 0.170
Nurse 61 0.789 0.172 0.792 0.177
−0.0036 0.005
Consultant 51 0.799 0.165 0.829 0.157 0.0044 0.005
Consultant vs. nurse 51  0.0076 0.006
N IBDQ-B score 
(baseline)
IBDQ-B score 
(6 months)
Incremental change 
in IBDQ-B score vs. 
booklet groupa
Based on participants with IBDQ-B data at baseline and 6 months
Booklet 57 52.53 12.66 57.46 12.86
Nurse 66 52.95 10.13 62.00 10.21 4.12b 2.0 (SE)
Consultant 59 52.62 10.93 60.68 10.76 5.07b 2.16 (SE)
Consultant vs. nurse 0.95 1.68 (SE)
Notes: aIncremental QALY gain based on ordinary least squares regression estimates controlling for baseline utility.bDifferences between groups statistically significant at a 
5% level using two-sample t-test. Within-group changes were significant for nurse and consultant, but not for booklet.5
Abbreviations: IBDQ-B, Inflammatory Bowel Disease Questionnaire; SD, standard deviation; QALY, quality-adjusted life year; SE, standard error; SF-12, Medical Outcomes 
Study’s Short-Form 12.
Table 3 Cost-utility and cost-effectiveness analysis
Cost-utility analysis N Incremental cost (£) Incremental mean change 
in QALY
ICER (incremental cost 
per QALY gained)
Nurse vs. booklet 108 £895
−0.0036 Dominated
Consultant vs. booklet 98 £1102 0.0044 £250,455
Consultant vs. nurse 112 £207 0.0076 £25,875
Cost effectiveness 
analysis
N Incremental cost (£) Incremental mean change 
in IBDQ-B score
ICER (incremental cost per 
6-point IBDQ-B score gain)
Nurse vs. booklet 123 £878 4.12 £1279
Consultant vs. booklet 116 £1076 5.07 £1273
Consultant vs. nurse 125 £198 0.95 £1251
Abbreviations: IBDQ-B, Inflammatory Bowel Disease Questionnaire; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
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Figure 1 QALY scores: cost-effectiveness planes and cost-effectiveness acceptability frontier.
Abbreviation: QALY, quality-adjusted life years.
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Figure 2 IBDQ-B scores: cost-effectiveness planes and cost-effectiveness acceptability frontier.
Abbreviation: IBDQ-B, inflammatory bowel disease questionnaire.
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Discussion
The provision of algorithmic-based treatment to patients 
experiencing enduring gastrointestinal symptoms after radio-
therapy for cancer costs ~£1100 when delivered by a consul-
tant gastroenterologist and £895 when delivered by a specialist 
nurse (British pounds 2013). Symptoms improved to a similar 
extent in both algorithmic care groups over a 6-month period, 
and significantly more than in a group of patients receiving 
only a self-help booklet. At a societal willingness to pay below 
£1280 for a clinically significant improvement in symptoms 
(i.e., at least a 6-point change in IBDQ-B), the booklet has a 
high probability of being the most cost-effective option. As 
the willingness to pay rises above that level, the nurse and then 
the consultant become more likely to be cost-effective, but the 
probabilities do not rise above 50% until a willingness to pay 
of about £3000 is reached. Simply put, the algorithmic care 
achieves better outcomes as reflected in IBDQ-B scores, and 
this comes at an additional cost of around £1000.
The finding that outcomes of nursing care are largely 
equivalent to those of doctors is consistent with other stud-
ies as shown in endoscopy clinics26 and in soft tissue clinics 
in an emergency department.27 As well as having similar 
outcomes, the use of nurses has also been shown to reduce 
costs compared to doctors in outpatient departments28 and 
rheumatoid arthritis clinics.29 As other studies compare the 
two types of practitioners in the delivery of usual care, this 
study focused on the evaluation of a new intervention. Lower 
costs associated with the nurse-led care was largely attribut-
able to salary differences, and less medication prescribing; 
the application of the algorithm resulted in very similar 
diagnostic and non-pharmacological treatment costs for the 
two types of practitioners.
Although patients in the trial recorded clinically and 
statistically significant improvements in bowel symptoms as 
a result of the nurse and consultant interventions, commensu-
rate changes in generic health-related quality of life (QALYs) 
were not found. At the upper limit of the NICE threshold of 
willingness to pay of £30,000/QALY gained, the booklet 
arm has a near 100% chance of being the most cost-effective 
option. The incremental cost of consultant- and nurse-led 
treatments, compared to usual care, were too high, given the 
small utility gains, to be deemed cost-effective options. A 
societal willingness to pay in the region of £250,000/QALY 
gained is required before the consultant treatment achieves a 
50% probability of being the most cost-effective option. The 
nurse option was not found to be cost-effective compared to 
either the booklet- or consultant-led care. A comparison of 
care of people with rheumatoid arthritis by nurse and rheu-
matologist similarly showed the nurse was not cost-effective, 
as measured using QALYs estimated from generic utility 
scores.29 Therefore, caution must be taken when considering 
provision of care based solely on the generic health-related 
quality of life instruments that may not capture the full patient 
benefit of symptom-specific interventions. The marginal 
cost of treating post-radiotherapy symptoms identified in 
this study (~£1000) is relatively small when considering 
the overall cost of the cancer treatment already incurred for 
this patient group. Moreover, inflammatory bowel disease, 
which affects equivalent numbers of people and incurs 
similar symptoms, is routinely managed through specialist 
supportive secondary care.30
The economic analysis had several limitations. Bias may 
have arisen from non-random missing data. The conversion of 
SF-12 scores to SF-6 and then EQ-5D utility may have caused 
lack of precision in the calculation of QALYs. In addition, 
given a significant change was detected in the disease-specific 
IBDQ-B measure, it is possible that the SF-12 instrument 
may have been insensitive to changes in the symptom-specific 
quality of life of these patients. Although attempts were made 
to gather data from participants on use of other services over 
the 6-month observation period, many did not return usable 
information so potential healthcare savings to offset the 
cost of the intervention could not be explored. The length of 
follow-up consultations was not recorded, and the assump-
tion of 15 minutes may underestimate the costs. The usual 
care comparison condition was not entirely representative 
of treatment as usual as many people with gastrointestinal 
symptoms after radiotherapy do not receive any information 
or treatment in the UK. Hence, provision of a booklet and 
the opportunity to receive treatment from the consultant if 
symptoms remained at 6 months represented an enhancement 
on usual care for people recruited to the trial.
Conclusion
The clinical trial and cost-effectiveness analysis were con-
ducted robustly and evaluated an important new treatment for 
cancer survivors. This patient group often tolerates significant 
gastrointestinal symptoms and reduced quality of life in the 
belief that this is the normal sequel to radiation therapy. 
Although evidence for cost-effectiveness according to the 
NICE criteria was not found in this study, participants in both 
intervention groups recorded, on average, significantly (statis-
tically and clinically) greater improvement in bowel symptoms 
than those in the booklet-only group. Monitoring the continu-
ing side effects of radiation therapy and providing treatment 
for radiation injury would add some £1000 to the overall pack-
age of care for cancer patients which, for example, currently 
costs between £10,000 and £15,000 for bowel cancer (based 
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on applying the GDP deflator to figures from 2007).31,32 The 
failure of the economic evaluation to show cost-effectiveness 
of the treatment algorithm in terms of cost per QALY gained 
may reflect the reliance of the criterion on a generic measure 
of health-related quality of life and should not be viewed in 
isolation. Improvements in this instance are highly symptom 
specific; therefore, relying on the generic measure of quality 
of life may not capture the full patient benefit from this inter-
vention, as evidenced by the clinical IBDQ-B results.5 The 
cost-effectiveness of the booklet suggests that a care pathway 
might be developed where patients with bowel symptoms after 
pelvic radiotherapy are offered the self-help booklet first, and 
if troublesome symptoms remain after 6 months, they are 
referred for specialist algorithmic care.
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